International Journal of Impotence Research最新文献

The present study assessed the accuracy of artificiaI intelligence-generated responses to frequently asked questions on erectile dysfunction. A cross-sectional analysis involved 56 erectile dysfunction-related questions searched on Google, categorized into nine sections: causes, diagnosis, treatment options, treatment complications, protective measures, relationship with other illnesses, treatment costs, treatment with herbal agents, and appointments. Responses from ChatGPT 3.5, ChatGPT 4, and BARD were evaluated by two experienced urology experts using the F1 and global quality scores (GQS) for accuracy, relevance, and comprehensibility. ChatGPT 3.5 and ChatGPT 4 achieved higher GQS than BARD in categories such as causes (4.5 ± 0.54, 4.5 ± 0.51, 3.15 ± 1.01, respectively, p < 0.001), treatment options (4.35 ± 0.6, 4.5 ± 0.43, 2.71 ± 1.38, respectively, p < 0.001), protective measures (5.0 ± 0, 5.0 ± 0, 4 ± 0.5, respectively, p = 0.013), relationships with other illnesses (4.58 ± 0.58, 4.83 ± 0.25, 3.58 ± 0.8, respectively, p = 0.006), and treatment with herbal agents (3 ± 0.61, 3.33 ± 0.83, 1.8 ± 1.09, respectively, p = 0.043). F1 scores in categories: causes (1), diagnosis (0.857), treatment options (0.726), and protective measures (1), indicated their alignment with the guidelines. There was no significant difference between ChatGPT 3.5 and ChatGPT 4 regarding answer quality, but both outperformed BARD in the GQS. These results emphasize the need to continually enhance and validate AI-generated medical information, underscoring the importance of artificiaI intelligence systems in delivering reliable information on erectile dysfunction.

Testicular prosthesis implantation is a valuable solution for the physical, cosmetic, and psychological challenges associated with testicular loss which may affect males of any age. We evaluated the safety and reliability of the new Rigicon Testi10^TM testicular prosthesis in adults and adolescents by performing an IRB-approved retrospective study of data drawn from Patient Information Forms (PIFs). A total of 427 patients (382 adults and 45 adolescents) had at least one testicular prosthesis implanted. Only one adult patient required revision surgery due to rupture of the Rigicon Testi10 ^TM saline-filled prosthesis. A 40-year-old patient was found to have a leaking prosthesis approximately one week postoperatively, which was suspected to be due to inadvertently punctured by the surgeon during the sterile saline filling process. There were no post-implantation revisions required for adolescent patients. According to our results, Kaplan-Meier calculation of survival from removal or revision was 99.8% for all patients at 54 months (99.7% for adults and 100% for adolescents). The complication rates among patients in this study are lower than those reported in previous published studies. Our study underscores the generally safe nature of testicular prosthesis implantation, as well as the very rare incidence of revision surgery for this new device.

The comment by Vandermaesen K and Albersen M [1] on our recent study on the oncological outcomes of penile squamous cell carcinoma (SCC) in a ≤50 years (younger) and >50 years (older) cohort of men [2] raised important points for areas of further research.

Correctly identified, the intentionally matched cohorts based on the stage of disease and surgical technique would limit a comprehensive evaluation of histopathological characteristics between the younger and older groups of men. However, the aim of our study was not to investigate this, but to understand whether the two groups of patients with similar stage of disease and surgical treatment would have different survival outcomes. We found that there were no differences in outcomes, except for overall survival. It is likely, as pointed out by Vandermaesen K and Albersen M [1] that the lower overall survival rate observed in the older cohort is associated with higher comorbidities. However, we did not compare data on comorbidities or Charlson scores to prove this. The observation that similar cancer staging in both age groups resulted in similar cancer-specific survival, recurrence-free and metastatic-free survivals implied that penile SCC in the younger patients is at least as aggressive as in older patients and should not be underestimated.

Male hypogonadism is a clinical syndrome that results in low testosterone levels and frequently leads to infertility. The syndrome occurs due to disruption at one or more levels of the hypothalamic-pituitary-gonadal axis. Testosterone replacement therapy (TRT) is the most common treatment utilised for male hypogonadism. However, long-acting forms of TRT leads to infertility and so is inappropriate for patients wishing to conceive. For patients who wish to remain fertile, nasal TRT, clomiphene citrate, exogenous gonadotropins, gonadotropin releasing hormone and aromatase inhibitors have been used as alternative treatment options with different degrees of success. A review of the literature was performed to identify the safety and efficacy of alternative treatment options. Gonadotropin releasing hormone can successfully induce spermatogenesis but is impractical to administer. Likewise, aromatase inhibitors have limited use due to inducing osteopenia. Nasal TRT may be a good treatment option for these patients, but its efficacy has so far only been demonstrated in small sample sizes. However, clomiphene citrate and exogenous gonadotropins are safe, offer good symptom control and can successfully induce fertility in hypogonadism patients.

This work aimed to evaluate the effects of the aqueous extract of Vepris afzelii roots on a rat model of hypogonadism. Phytochemical screening and acute toxicity of the extract were performed using different procedures. Hypogonadism was induced orally in adult Wistar rats using cyproterone acetate (30 mg/kg) for ten days. Besides six normal rats (10 ml/kg of distilled water, normal control), 30 hypogonadal rats were subdivided into five groups of six animals each, receiving for 14 days: distilled water (10 ml/kg, hypogonadal control), testosterone (4 mg/kg/3days) and the extract of V. afzelii (100, 200 and 400 mg/kg). Sexual behavior, sperm parameters, testes function and structure were assessed. Compared to the normal controls, significant (p = 0.0000) increases in mount (24 ± 0.94 seconds vs. 1200 ± 00 seconds) and intromission (49.16 ± 10.85 seconds vs. 1200 ± 00 seconds) latencies, and post-ejaculatory interval (381.72 ± 37.55 seconds vs. 1200 ± 00 seconds) were observed in all groups receiving cyproterone acetate on day 0. Total inhibitions of mounts (63.50 ± 8.91 vs. 00 ± 00), intromissions (36.66 ± 3.51 vs. 00 ± 00) (p = 0.0000), ejaculations (2.83 ± 00 vs. 00 ± 00, p = 0.0002) frequencies and mean copulatory interval (627.30 ± 81.80 vs. 00 ± 00, p = 0.0000) were also observed in these groups. Moreover, decreases in daily sperm production (2.65 ± 0.19 vs. 1.17 ± 0.08, p = 0.0498), percentage of sperm mobility (78.64 ± 8.41 vs. 10.12 ± 2.32), serum testosterone level (8.39 ± 0.63 ng/dl vs. 1.68 ± 0.19 ng/dl), diameter of seminiferous tubules (111.97 ± 0.51 µm vs. 94.51 ± 0.57 µm) and height of germinal epithelium (46.58 ± 0.34 µm vs. 33.74 ± 0.66 µm) (p = 0.0000) associated with increases in sperm transit (3.13 ± 0.45 vs. 11.07 ± 1.45, p = 0.0000) were also observed in these groups. Interestingly, compared to hypogonadal control and day 0, the administration of V. afzelii extract induced significant (p = 0.0000) improvements in all these altered parameters with 400 mg/kg being the most active dose. These results, attributed to saponins, flavonoids, polyphenols and triterpenes detected in this plant’s extract confirm its traditional usage and could be useful for the management of patients suffering from hypogonadism.

Previous research has found some peculiarities in sexual functioning of adults with attention deficit/hyperactivity disorder (ADHD). Using a set of questionnaires that had to be answered online, we assessed the prevalence of paraphilic fantasies and behaviors in a sample of 160 adults with ADHD in comparison to 75 adults without ADHD and evaluated the association between paraphilias and hypersexuality in the ADHD group. Both groups reported high rates of paraphilic fantasies and behaviors. ADHD individuals were more likely to report about very sexually arousing paraphilic fantasies (ADHD: 58.2% vs. non-ADHD: 40.5%; χ² = 6.323, p = 0.01) and behaviors (ADHD: 44.9% vs. non-ADHD: 28.4%; χ² = 5.774, p = 0.02). Furthermore, ADHD individuals reported on average about more very sexually arousing paraphilic behaviors compared to non-ADHD individuals (ADHD: M = 1.28, SD = 0.10 vs. non-ADHD: M = 0.81, SD = 0.09; T = 2.68, p < 0.01). Furthermore, in ADHD individuals both very sexually arousing paraphilic interests in masturbation fantasies (r(158) = 0.17, p = 0.03) and in sexual behaviors (r(158) =0.19, p = 0.02) showed a significant correlation with hypersexuality. In non-ADHD individuals no such significant correlation could be found. Altogether, it can be concluded that individuals with ADHD seem to be more prone to develop and act out paraphilic sexuality than those without ADHD, however, found differences were rather small. The results of the present study add to the current trend to depathologize paraphilic sexuality in the general as well as in clinical populations.